Codexis (CDXS) Stake Lifted by BlackRock Inc.

BlackRock Inc. lifted its holdings in shares of Codexis (NASDAQ:CDXS) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,672,981 shares of the biotechnology company’s stock after purchasing an additional 18,193 shares during the quarter. BlackRock Inc. owned 5.53% of Codexis worth $22,320,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of CDXS. Wells Fargo & Company MN grew its holdings in shares of Codexis by 156.4% during the fourth quarter. Wells Fargo & Company MN now owns 1,002,086 shares of the biotechnology company’s stock worth $8,367,000 after purchasing an additional 611,289 shares in the last quarter. Royce & Associates LP purchased a new stake in Codexis in the third quarter worth approximately $1,089,000. Prescott Group Capital Management L.L.C. boosted its stake in Codexis by 4.2% in the fourth quarter. Prescott Group Capital Management L.L.C. now owns 2,133,568 shares of the biotechnology company’s stock worth $17,815,000 after buying an additional 86,356 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in Codexis by 26.4% in the fourth quarter. Essex Investment Management Co. LLC now owns 362,980 shares of the biotechnology company’s stock worth $3,031,000 after buying an additional 75,895 shares in the last quarter. Finally, Pratt Collard Advisory Partners LLC purchased a new stake in Codexis in the fourth quarter worth approximately $566,000. 70.84% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

NASDAQ:CDXS opened at $11.40 on Monday. The company has a market cap of $603.16, a PE ratio of -22.80 and a beta of -1.73. Codexis has a fifty-two week low of $3.95 and a fifty-two week high of $13.60. The company has a quick ratio of 1.76, a current ratio of 1.80 and a debt-to-equity ratio of 0.02.

Codexis (NASDAQ:CDXS) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.03). The company had revenue of $21.70 million for the quarter, compared to analysts’ expectations of $22.97 million. Codexis had a negative net margin of 45.97% and a negative return on equity of 103.42%. The business’s revenue for the quarter was up 117.0% compared to the same quarter last year. During the same period last year, the company posted ($0.07) EPS. sell-side analysts anticipate that Codexis will post -0.25 earnings per share for the current year.

CDXS has been the subject of several research reports. Zacks Investment Research lowered Codexis from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. ValuEngine raised Codexis from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, HC Wainwright set a $12.00 target price on Codexis and gave the stock a “buy” rating in a research note on Monday, March 12th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $9.75.

In related news, Director Thomas R. Baruch sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $11.05, for a total transaction of $276,250.00. Following the completion of the transaction, the director now owns 184,670 shares in the company, valued at $2,040,603.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Dennis P. Wolf sold 41,666 shares of the company’s stock in a transaction that occurred on Tuesday, March 27th. The shares were sold at an average price of $11.15, for a total value of $464,575.90. Following the transaction, the director now owns 157,920 shares of the company’s stock, valued at approximately $1,760,808. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,337 shares of company stock valued at $1,187,683. Insiders own 9.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/16/codexis-cdxs-stake-lifted-by-blackrock-inc.html.

Codexis Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply